Immunotherapy-related hypophysis is emerging as an important cause of hypopituitarism in cancer patients treated with cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) inhibitors. The gene discussed is CTLA4; the disease is hypophysitis.